Alternatives to GeneSort

Comprehensive whole-genome monitoring for cancer recurrence and progression.

Nucleix is a liquid biopsy company developing early cancer detection solutions using methylation analysis.

Making targeted DNA sequencing as common, fast, and affordable as a blood test.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

Advanced diagnostics for preventative health and personalized cancer treatment using AI and genomics.

Personalized medicine startup focused on accurate cancer treatment through advanced diagnostics and functional drug sensitivity testing.

Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.

AI-powered multi-omics platform for early breast cancer detection and risk prediction.

Variantyx is a precision medicine company offering comprehensive genomic testing solutions for rare genetic disorders, reproductive health, and oncology.

Genoox provides a cloud-based AI platform for genomic data analysis, connecting clinicians and healthcare organizations.

Data-driven drug discovery and development company using machine learning and high-throughput biology.

AI-powered platform for profiling cancer biomarkers from digitized biopsy images.

Bioinformatics platform for rapid discovery and validation of precision mental health treatments.

Visby Medical develops and manufactures instrument-free, PCR-quality rapid diagnostic tests for infectious diseases at the point of care.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Digital therapeutics platform enhancing drug efficacy and safety through personalized software.

Precision oncology company developing cancer therapies guided by proprietary functional genomics.

Israeli-UK biotech company developing novel RNA therapeutics for rare genetic diseases.

Leveraging proteomic pattern analysis to personalize cancer treatment and improve patient outcomes.

Developing a liquid biopsy blood test for early disease detection and monitoring using epigenetic information.